Spark Therapeutics Tops $1 Billion in Financing with Latest Public Offering

September 1, 2017: By Joan McKenna

SparkSpark Therapeutics has raised about $380.4 million in a public offering of 5.3 million shares of common stock, the Philadelphia gene therapy company announced Aug. 9.

The company says it has now secured $1 billion in total financing. Spark was founded in March 2013.

It is developing gene therapies that address inherited retinal diseases, neurodegenerative diseases, and diseases that can be addressed by targeting the liver, such as hemophilia.

Spark’s most advanced candidate, with the proposed trade name Luxturna (voretigene neparvovec), is currently under priority review with the US FDA for the treatment of biallelic RPE65-mediated inherited retinal disease. The company has filed for marketing approval with the EMA for the treatment of vision loss due to Leber congenital amaurosis or retinitis pigmentosa caused by confirmed biallelic RPE65 mutations. Luxturna has received breakthrough therapy and orphan status from the FDA, as well as orphan status from the EMA. Spark’s pipeline also includes SPK-7001 in an ongoing Phase I/II clinical trial for choroideremia.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and Cowen and Company, LLC, acted as book-running managers for the offering.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel to Review Aerie’s Rhopressa in October

Johnson & Johnson Vision Acquires Online Contact Lens Business Sightbox

Novartis Returns OUS Rights for Jetrea to ThromboGenics

Eyevance Licenses Zerviate from Nicox for US Commercialization

Two Eye Projects Fail to Make Final Round for $100M Grant

Ophthotech Begins Phase IIa Trial for Zimura in Wet AMD

Graybug Vision Begins Phase I/II Trial for Candidate in Wet AMD

BioTime Receives $1.56 Million NIH Grant to Advance OpRegen for Dry AMD

FDA Approves Mvasi, a Biosimilar of Avastin Co-developed by Amgen, Allergan

Carl Zeiss Meditec Launches Zeiss Clarus 500 Ultra-Widefield Fundus Imaging System in US

Imprimis Appeals to Public Sentiment in Fiery Response to Allergan Lawsuit

Roche’s Lampalizumab Fails in Phase III Study in Geographic Atrophy

Aldeyra Reports Positive Phase IIa Results for Dry Eye Candidate ADX-102

US Denies Coherus’ Petitions Challenging AbbVie’s Patent for Humira

Ocular Therapeutix Names Michael Goldstein, MD, Chief Medical Officer

PhysIOL Agrees to Acquire Majority Stake in Italian Optikon

Rayner Creates US Subsidiary in New York

Inotek to Merge with Gene Therapy Startup Rocket

Allergan Agrees to $13.75 Million Deal with Tribe to Protect Restasis Patents

Ellex to Boost Production of iTrack Microcatheters to 50 Thousand a Year

Coming soon

2017 Retinal Pharmaceuticals and Biologics Report: A Global Market Analysis for 2016 to 2022